The first evaluation of the effectiveness of canine vaccination schedule by two commercial vaccines in Iran

Abstract

BackgroundCanine Parvovirus type 2 (CPV-2) is a member of the Parvoviridae family with a global distribution and causes pathogenicity in puppies aged from 6 weeks to 6 months. It should be noted that Maternally Derived Antibodies (MDA) have protection against CPV-2 in the first weeks of puppies’ life. However, MDA declines with age. The most important influential factor is timely vaccination against CPV-2.MethodsIn this study, 24 healthy 8-week-old terrier puppies were selected and divided into three identical groups based on a randomized, double-blind comparative trial. One of which was called the control group that was injected with the physiological serum. The second group was the group A that was vaccinated by the vaccine provided by Biocan DHPPi+L (Bioveta, Czech). The third group was group B that was vaccinated by the vaccine of Duramune Max 5 + LCI / GP (Fort Dodge Animal Health, USA) from 8 to 16 weeks of their life at every 4 weeks. Then serum samples were analyzed with HI and ELISA tests.ResultsThe MDA titer was protective in some puppies until 18 weeks of age. Also, after the first vaccination, all puppies had a protective titer against CPV-2, and Duramune vaccine had seroconverted after the first injection and Biocan had seroconverted after the second injection.ConclusionsIt is recommended that to reduce the risk of vaccine failure: such as the MDA titer should be measured in puppies before designing a vaccination schedule.